Statistics for Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

Total visits

views
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102 292

Total visits per month

views
May 2024 0
June 2024 0
July 2024 0
August 2024 0
September 2024 0
October 2024 0
November 2024 0

File Visits

views
Kornblum_2018_randomized.pdf 655

Top country views

views
United States 175
China 8
Germany 8
Sweden 5
Ukraine 5
Canada 4
Italy 4
Netherlands 4
Egypt 3
United Kingdom 2
Indonesia 2
India 2
Russia 2
South Africa 2
Australia 1
Belgium 1
Brazil 1
Switzerland 1
Ecuador 1
France 1
South Korea 1
North Macedonia 1
Mexico 1
Malaysia 1
Turkey 1
Taiwan 1

Top city views

views
Wilmington 51
Fairfield 18
Washington 13
Cambridge 9
Houston 9
White Plains 7
Jacksonville 6
Lake Mary 6
Kiev 5
Kiez 5
San Francisco 5
Stockholm 4
Toronto 4
Arnhem 3
Beijing 2
Boston 2
Duncan 2
Jakarta 2
Scottsdale 2
Shanghai 2
Wynberg 2
Ahmadabad 1
Albi 1
Amaro 1
Amsterdam 1
Ashburn 1
Basel 1
Brooklyn 1
Brugge 1
Catania 1
Dearborn 1
Decatur 1
Elmshorn 1
Fort Worth 1
Garching 1
Gothenburg 1
Gunzenhausen 1
Ibarra 1
Indianapolis 1
Kansas City 1
Kemmerer 1
Lexington 1
Madison 1
Monrovia 1
Moscow 1
Nanterre 1
New York 1
Newtown 1
Oxford 1
Palo Alto 1
Philadelphia 1
Portland 1
Rimini 1
Sacramento 1
Saint Louis 1
Saint Petersburg 1
Seoul 1
Seremban 1
Skopje 1
Taipei 1
Tallahassee 1
University 1
Upper Marlboro 1
Woburn 1
Zhongyuan 1